Longitudinal analysis of tumor-specific T-cel immunity in irresectable stage IIIc and stage IV melanoma patients

Longitudinal analysis of tumor-specific T-cel immunity in irresectable stage IIIc and stage IV melanoma patients - Tumor-specific immunity in melanoma patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36481

Enrollment

Registered

2011-04-04

Start date

2011-04-06

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanoma skin cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Histologically or cytologically proven irresectable stage IIIc or IV melanoma -Age above 18 years -WHO performance score 0, 1 or 2 at the time of study entry -Written informed consent

Exclusion criteria

Exclusion criteria: -Severe anemia (Hb

Design outcomes

Primary

Measure	Time frame
Immunologic monitoring	—

Secondary

Measure	Time frame
None.	—

Countries

Netherlands

Outcome results